FDA aligns on RP-A501: Rocket Pharmaceuticals stock sits 71.22 percent below target

Published on 10/02/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Needham set a USD 9.00 target on September 16, 2026. Rocket Pharmaceuticals stock costs EUR 2.32 on October 2, 2026 after EUR 2.32.

RCKT, US77313F1066, Illustration mit AI erstellt.

Rocket Pharmaceuticals (ISIN US77313F1066) was trading at EUR 2.32 at Lang & Schwarz on October 2, 2026, at 3:14 p.m. CEST, unchanged from the prior close of EUR 2.32. On September 15, 2026, the company said the FDA aligned with continued enrollment and dosing in the RP-A501 Phase 2 trial for Danon disease. The primary-market context was USD 2.59 on Nasdaq on October 1, 2026, and the USD 9.00 Needham target places the share price 71.22 percent below that target.

FDA clears a 12-patient path

According to Rocket Pharmaceuticals in its September 15, 2026 release, the FDA confirmed a pivotal efficacy population of 12 male patients and continued dosing under a recalibrated protocol.

Three patients treated under the modified protocol already count toward the 12-patient population, leaving nine additional patients to be enrolled and treated. Rocket expects to complete dosing of those remaining patients by mid-2027, while the primary assessment is planned at 12 months.

Analyst target stays far above Nasdaq price

MarketBeat reported on September 16, 2026, that Needham upgraded Rocket Pharmaceuticals from Hold to Buy and set a USD 9.00 price target. The same report said Chardan reaffirmed a Buy rating with an USD 11.00 target, while the broader consensus remained Hold.

The valuation gap is material but does not remove development risk. Rocket reported adjusted earnings per share of USD 1.08 for the second quarter of 2026 against a USD 0.86 consensus estimate, while the company recorded no revenue in that period, according to Nasdaq.

October 6 webinar adds the next date

Rocket plans a Danon disease program webinar on October 6, 2026, at 4:30 p.m. ET, according to its September 15 release. The event is set to provide a broader update on RP-A501 as the company advances the modified Phase 2 protocol.

RCKT price holds at EUR 2.32

Rocket Pharmaceuticals stock was trading at EUR 2.32 at Lang & Schwarz on October 2, 2026, at 3:14 p.m. CEST, unchanged from the prior close of EUR 2.32. Its 52-week Nasdaq range was USD 2.51 to USD 5.45, with market capitalization of USD 282.8 million as of October 2, 2026.